We are live on ! Find out more
ARNA

Arena Pharmaceuticals Inc

Delisted

ARNA was delisted on the 10th of March, 2022.

129 hedge funds and large institutions have $401M invested in Arena Pharmaceuticals Inc in 2014 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 42 increasing their positions, 37 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

71% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 14

14% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 37

7% more funds holding

Funds holding: 121129 (+8)

11% less capital invested

Capital invested by funds: $451M → $401M (-$50.3M)

46% less call options, than puts

Call options by funds: $10.8M | Put options by funds: $19.8M

Holders
129
Holders Change
+8
Holders Change %
+6.61%
% of All Funds
3.44%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
24
Increased
42
Reduced
37
Closed
14
Calls
$10.8M
Puts
$19.8M
Net Calls
-$9.03M
Net Calls Change
+$3.61M
Name Holding Trade Value Shares
Change
Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$101M -$2.14M -52,604 -2%
Vanguard Group
2
Vanguard Group
Pennsylvania
$48.2M +$2.79M +68,822 +5%
BFA
3
BlackRock Fund Advisors
California
$28.4M +$2.93M +72,195 +10%
State Street
4
State Street
Massachusetts
$27.9M +$1.94M +47,751 +6%
O
5
OppenheimerFunds
New York
$24.3M
DM
6
Deerfield Management
New York
$24.1M +$4.49M +110,574 +19%
BIT
7
BlackRock Institutional Trust
California
$21.6M +$726K +17,877 +3%
Susquehanna International Group
8
Susquehanna International Group
Pennsylvania
$13.4M -$316K -7,774 -2%
Invesco
9
Invesco
Georgia
$10.3M +$1.2M +29,675 +11%
Northern Trust
10
Northern Trust
Illinois
$8.51M -$437K -10,776 -4%
Norges Bank
11
Norges Bank
Norway
$6.7M
Millennium Management
12
Millennium Management
New York
$5.67M +$6.56M +161,659 +10,104%
Group One Trading
13
Group One Trading
Illinois
$5.63M +$317K +7,800 +5%
NI
14
Numeric Investors
Massachusetts
$4.61M +$5.39M +132,870 New
Geode Capital Management
15
Geode Capital Management
Massachusetts
$4.47M +$147K +3,609 +3%
Bank of New York Mellon
16
Bank of New York Mellon
New York
$4.11M -$173K -4,256 -3%
D.E. Shaw & Co
17
D.E. Shaw & Co
New York
$4.11M +$3.98M +98,098 +483%
TCIM
18
TIAA CREF Investment Management
New York
$4.05M -$225K -5,548 -5%
OAM
19
Oxford Asset Management
United Kingdom
$3.26M +$3.8M +93,724 New
TA
20
Teachers Advisors
New York
$3.11M -$3.17K -78 -0.1%
California Public Employees Retirement System
21
California Public Employees Retirement System
California
$3.04M
Barclays
22
Barclays
United Kingdom
$2.16M +$2.24M +55,166 +328%
Charles Schwab
23
Charles Schwab
California
$2.14M +$313K +7,717 +14%
BIM
24
BlackRock Investment Management
Delaware
$2.08M -$19.2K -474 -0.8%
CS
25
Credit Suisse
Switzerland
$2M +$1.12M +27,711 +92%

ARNA Hedge Fund Activity: Q4 2014 in Review

129 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Arena Pharmaceuticals Inc (ARNA) for Q4 2014, worth a combined $401M — down 11% from $451M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new ARNA positions and 14 closed out — a net gain of 10 holders — while 42 added to existing stakes and 37 trimmed.

The largest buyer was Millennium Management, adding an estimated $6.56M. The largest seller was Guggenheim Capital, cutting an estimated $3.02M.

  • 129 institutional investors held Arena Pharmaceuticals Inc (ARNA) as of Q4 2014, up from 121 in Q3 2014.
  • Funds reported $401M of Arena Pharmaceuticals Inc stock for Q4 2014, down 11% quarter-over-quarter.
  • 24 funds opened new Arena Pharmaceuticals Inc positions in Q4 2014 and 14 closed out, a net change of +10 holders.
  • The largest Arena Pharmaceuticals Inc buyer in Q4 2014 was Millennium Management, an estimated $6.56M added.
  • The largest Arena Pharmaceuticals Inc seller in Q4 2014 was Guggenheim Capital, an estimated $3.02M sold.

Based on aggregated 13F filings for Q4 2014.